Home › Companies › LYELL IMMUNOPHARMA INC. › 2023-2024
Compiled from SEC Form N-PX filings and LYELL IMMUNOPHARMA INC.’s Form 8-K, filed 2024-06-14 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Proxy season: 2023-2024
Explore LYELL IMMUNOPHARMA INC. in the interactive database Compare manager voting policies
These tallies are LYELL IMMUNOPHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-06-14 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Elizabeth Nabel, M.D. | 147,841,830 | -- | -- | 16,168,964 | 34,804,776 | Majority: yes |
| Elect Director: Lynn Seely, M.D. | 150,085,827 | -- | -- | 13,924,967 | 34,804,776 | Majority: yes |
| 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. | 198,604,866 | 153,727 | 56,977 | -- | -- | Majority: yes |
| 3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. | 108,778,036 | 46,997,736 | 8,235,022 | -- | 34,804,776 | Majority: yes |
Source: LYELL IMMUNOPHARMA INC., Form 8-K, filed with the SEC on 2024-06-14 — read the filing on EDGAR.
Each item below shows how the 139 asset managers that disclosed a LYELL IMMUNOPHARMA INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
70% Majority: yes · of votes cast
LYELL IMMUNOPHARMA INC.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.”): 108,778,036 for, 46,997,736 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 254,939,222 outstanding shares: 43% for, 18% against (61% of the company cast a for/against vote).
The 138 asset managers below cast 50.8% of the shares they voted on this item FOR (57,677,209 for, 55,939,895 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 36,412,716 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 12,484,529 | 0 | 0 | Against |
| Vanguard | 0 | 11,290,159 | 0 | 0 | Against |
| Foresite Capital Management IV, LLC | 8,325,000 | 0 | 0 | 0 | For |
| BlackRock | 70,543 | 6,911,041 | 0 | 0 | Against |
| GV Management Company, L.L.C. | 5,865,125 | 0 | 0 | 0 | For |
| Fidelity | 0 | 5,727,879 | 0 | 0 | Against |
| Opaleye Management Inc. | 2,980,000 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 2,561,224 | 0 | 0 | Against |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 2,689,472 | 0 | 0 | Against |
| State Street | 2,164,429 | 13,625 | 0 | 0 | For |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 0 | 1,556,226 | 0 | 0 | Against |
| BROWN ADVISORY INC | 0 | 1,519,807 | 0 | 0 | Against |
| MFS | 0 | 1,469,278 | 0 | 0 | Against |
| Northern Trust | 1,073,295 | 2,402 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 0 | 1,012,488 | 0 | 0 | Against |
| Invenomic Capital Management LP | 0 | 866,958 | 0 | 0 | Against |
| NORTHERN LIGHTS FUND TRUST II | 0 | 801,016 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 0 | 741,337 | 0 | 0 | Against |
| CANADA PENSION PLAN INVESTMENT BOARD | 0 | 588,235 | 0 | 0 | Against |
| SEI | 0 | 392,308 | 0 | 0 | Against |
| Invesco | 0 | 385,874 | 0 | 0 | Against |
| Clarius Group, LLC | 382,764 | 0 | 0 | 0 | For |
| John Hancock | 0 | 376,969 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 334,394 | 0 | 0 | Against |
Showing the 25 largest of 138 asset managers. See all 138 in the interactive database.
Combines 3 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
LYELL IMMUNOPHARMA INC.’s own tally for this item (“Elect Director: Elizabeth Nabel, M.D.”): 147,841,830 for, 16,168,964 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 254,939,222 outstanding shares: 58% for, 6% withheld (64% of the company cast a for/withheld vote).
The 46 asset managers below cast 100% of the shares they voted on this item FOR (24,885,226 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,065,256 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,549,552 | 0 | 0 | 0 | For |
| BlackRock | 4,607,087 | 0 | 0 | 0 | For |
| Fidelity | 61,222 | 0 | 3,440,456 | 0 | Abstain |
| MFS | 0 | 0 | 1,469,278 | 0 | Abstain |
| Charles Schwab | 1,280,612 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST II | 801,016 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 334,394 | 0 | 0 | 0 | For |
| John Hancock | 234,729 | 0 | 70,870 | 0 | For |
| Equitable | 72,262 | 0 | 174,830 | 0 | Abstain |
| Lincoln Financial | 143,900 | 0 | 83,215 | 0 | For |
| Global X | 221,597 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 167,700 | 0 | Abstain |
| Nushares ETF Trust | 0 | 0 | 156,675 | 0 | Abstain |
| Pacific Life | 69,275 | 0 | 82,998 | 0 | Abstain |
| ETF Series Solutions | 0 | 0 | 129,875 | 0 | Abstain |
| SEI | 129,836 | 0 | 0 | 0 | For |
| New York Life | 0 | 0 | 112,211 | 0 | Abstain |
| TARGET PORTFOLIO TRUST | 87,700 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 81,594 | 0 | Abstain |
| Bridge Builder Trust | 73,626 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 58,585 | 0 | Abstain |
| Managed Portfolio Series | 47,763 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 44,862 | 0 | Abstain |
| ETFis Series Trust I | 0 | 0 | 42,892 | 0 | Abstain |
Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
LYELL IMMUNOPHARMA INC.’s own tally for this item (“Elect Director: Lynn Seely, M.D.”): 150,085,827 for, 13,924,967 withheld, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 254,939,222 outstanding shares: 59% for, 5% withheld (64% of the company cast a for/withheld vote).
The 46 asset managers below cast 100% of the shares they voted on this item FOR (26,842,567 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,065,256 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,549,552 | 0 | 0 | 0 | For |
| BlackRock | 4,607,087 | 0 | 0 | 0 | For |
| Fidelity | 61,222 | 0 | 3,440,456 | 0 | Abstain |
| MFS | 1,469,278 | 0 | 0 | 0 | For |
| Charles Schwab | 1,280,612 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST II | 801,016 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 334,394 | 0 | 0 | 0 | For |
| John Hancock | 234,729 | 0 | 70,870 | 0 | For |
| Equitable | 247,092 | 0 | 0 | 0 | For |
| Lincoln Financial | 143,900 | 0 | 83,215 | 0 | For |
| Global X | 221,597 | 0 | 0 | 0 | For |
| Invesco | 167,700 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 0 | 0 | 156,675 | 0 | Abstain |
| Pacific Life | 152,273 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 129,875 | 0 | Abstain |
| SEI | 129,836 | 0 | 0 | 0 | For |
| New York Life | 0 | 0 | 112,211 | 0 | Abstain |
| TARGET PORTFOLIO TRUST | 87,700 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 81,594 | 0 | Abstain |
| Bridge Builder Trust | 73,626 | 0 | 0 | 0 | For |
| Voya | 58,585 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 47,763 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 44,862 | 0 | Abstain |
| ETFis Series Trust I | 0 | 0 | 42,892 | 0 | Abstain |
Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
LYELL IMMUNOPHARMA INC.’s own tally for this item (“2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 198,604,866 for, 153,727 against, per its Form 8-K filed 2024-06-14 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 254,939,222 outstanding shares: 78% for, 0.1% against (78% of the company cast a for/against vote).
The 46 asset managers below cast 100% of the shares they voted on this item FOR (31,132,345 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,065,256 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,549,552 | 0 | 0 | 0 | For |
| BlackRock | 4,607,087 | 0 | 0 | 0 | For |
| Fidelity | 3,501,678 | 0 | 0 | 0 | For |
| MFS | 1,469,278 | 0 | 0 | 0 | For |
| Charles Schwab | 1,280,612 | 0 | 0 | 0 | For |
| NORTHERN LIGHTS FUND TRUST II | 801,016 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 334,394 | 0 | 0 | 0 | For |
| John Hancock | 305,599 | 0 | 0 | 0 | For |
| Equitable | 247,092 | 0 | 0 | 0 | For |
| Lincoln Financial | 227,115 | 0 | 0 | 0 | For |
| Global X | 221,597 | 0 | 0 | 0 | For |
| Invesco | 167,700 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 156,675 | 0 | 0 | 0 | For |
| Pacific Life | 152,273 | 0 | 0 | 0 | For |
| ETF Series Solutions | 129,875 | 0 | 0 | 0 | For |
| SEI | 129,836 | 0 | 0 | 0 | For |
| New York Life | 112,211 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 87,700 | 0 | 0 | 0 | For |
| American Century | 81,594 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 73,626 | 0 | 0 | 0 | For |
| Voya | 58,585 | 0 | 0 | 0 | For |
| Managed Portfolio Series | 47,763 | 0 | 0 | 0 | For |
| ProShares | 44,862 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 42,892 | 0 | 0 | 0 | For |
Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.
Ranked by the number of LYELL IMMUNOPHARMA INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 254,939,222 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARCH Venture Management, LLC | 14.28% |
| 2 | T. Rowe Price | 4.90% |
| 3 | Vanguard | 4.43% |
| 4 | Foresite Capital Management IV, LLC | 3.27% |
| 5 | BlackRock | 2.74% |
| 6 | GV Management Company, L.L.C. | 2.30% |
| 7 | Fidelity | 2.25% |
| 8 | Opaleye Management Inc. | 1.17% |
| 9 | Charles Schwab | 1.15% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 1.05% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Robert Nelsen | 14.31% | DEF14A |
| Entities affiliated with ARCH Venture Partners | 14.28% | DEF14A |
| Glaxo Group Limited | 11.87% | DEF14A |
| Milky Way Investments Group Limited | 7.91% | DEF14A |
| Gemini Investments, L.P. | 5.92% | DEF14A |
| BlackRock, Inc. | 5.61% | DEF14A |
| The Vanguard Group | 5.34% | 13G |
| Richard D. Klausner, M.D. | 4.71% | DEF14A |
| T. Rowe Price | 2.64% | 13F |
| Hans Bishop | 1.87% | DEF14A |
Percentages above are of 254,939,222 shares outstanding, as reported by LYELL IMMUNOPHARMA INC. on its Form 10-Q dated 2024-05-02 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from LYELL IMMUNOPHARMA INC.’s 10-Q dated 2024-05-02. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At LYELL IMMUNOPHARMA INC.'s shareholder meeting held 2024-06-14, in the 2023-2024 proxy season, 139 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 684 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE… — FOR was 70% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: LYELL IMMUNOPHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-06-14.
LYELL IMMUNOPHARMA INC. proxy season coverage: 2023-2024 (this page).